Sean Laaman Stock Analyst Profile - Morgan Stanley Research Coverage - Stocknear

Sean Laaman

Stock Analyst at Morgan Stanley

(4.9)
# 663
Out of 5,504 analysts
11
Total ratings
Success rate
Average return

9 Stocks

Name Action PT Current % Upside Ratings Updated
EXEL Exelixis
Maintains: Overweight
46 50
40.96 22.07% 2 Sep 17, 2025
IRON Disc Medicine
Maintains: Overweight
85 90
66.82 34.69% 2 Aug 18, 2025
AXSM Axsome Therapeutics
Assumes: Overweight
190
120.14 58.15% 1 Jul 3, 2025
CERT Certara
Assumes: Equal-Weight
16
13.37 19.67% 1 Jul 3, 2025
ONC BeOne Medicines
Maintains: Overweight
313 330
338.94 -2.64% 1 Jun 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Underweight
3 2
3.17 -52.68% 1 Mar 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Overweight
67
68.38 -2.02% 1 Feb 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Overweight
300
n/a n/a 1 Dec 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
169
278.53 -39.32% 1 Oct 27, 2023